Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
Ambu fails to live up to revenue forecasts
The number of endoscopes sold is significantly higher than what the market had predicted in Ambu's second quarter. However, this has not brought about the kind of revenue that analysts had expected. The full-year outlook is maintained.
Tough competition forces innovation at Ambu
Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.
Electronics firm presents long-awaited hearing solution
Following an approval from the US FDA in 2018, technology firm Bose is now launching its new low-cost, self-tuning hearing aid which works in the same way as the upcoming OTC devices in the US.
Analyst on new Bose hearing aid: "Won't disrupt Danish manufacturers"
US electronics company Bose's announced launch of a new, cheap self-tuning hearing aid won't cause sales to plummet for established hearing aid manufacturers, analysts believe. Demant welcomes the competition and WSA plans to test Bose's new solution to understanding its technology.
Ambu gets US approval for new product
Ambu expects to launch Vivasight 2 on the US market during Q3 of its financial year 2020/2021
Manager, SOX Compliance - Zealand Pharma 
QA Professional with a broad interest in quality 
Associate Director, GMP QA, Commercial Operations – Y-mAbs Therapeutics 
Manager, QA GMP - Genmab 
Senior/Principal PV Associate - Lundbeck 
Senior Manager – Corporate Development and M&A, Orifarm 
Experienced Content Manager, life science - UNEEG medical 
(Senior) Regulatory Science Specialist - IWA Consulting 
Scientific Data Engineer - Novo Nordisk 
Cross Functional CMC/Safety Toxicologist, Ascendis Pharma 
Head of DS Manufacturing Facilities & EHS - Bacthera